D.E. Shaw & Co
ABOS icon

D.E. Shaw & Co’s Acumen Pharmaceuticals ABOS Stock Holding History

D.E. Shaw & Co’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-55,007
Closed -$133K – 4495
2024
Q2 		$133K Buy
+55,007
New +$175K ﹤0.01% 4131
2024
Q1 		– Sell
-138,029
Closed -$530K – 4291
2023
Q4 		$530K Buy
+138,029
New +$410K ﹤0.01% 3488
2023
Q3 		– Sell
-60,504
Closed -$291K – 4217
2023
Q2 		$291K Sell
60,504
-99,704
-62% -$477K ﹤0.01% 3604
2023
Q1 		$650K Sell
160,208
-81,633
-34% -$426K ﹤0.01% 3421
2022
Q4 		$1.31M Buy
241,841
+77,199
+47% +$519K ﹤0.01% 3257
2022
Q3 		$1.65M Buy
164,642
+146,065
+786% +$838K ﹤0.01% 3170
2022
Q2 		$87K Sell
18,577
-29,599
-61% -$111K ﹤0.01% 4753
2022
Q1 		$188K Buy
48,176
+21,009
+77% +$114K ﹤0.01% 4880
2021
Q4 		$184K Buy
27,167
+8,853
+48% +$97.3K ﹤0.01% 4908
2021
Q3 		$272K Buy
+18,314
New +$305K ﹤0.01% 4413

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

D.E. Shaw & Co's ABOS Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Acumen Pharmaceuticals (ABOS) in Q3 2024, closing a stake of 55,007 shares — an estimated $133K sold.

D.E. Shaw & Co first reported a position in ABOS in Q3 2021 and held it in 10 quarters. The position peaked at $1.65M in Q3 2022. 73 funds tracked by Wall St. Rank hold ABOS as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Acumen Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 55,007 Acumen Pharmaceuticals shares in Q3 2024, an estimated $133K.
  • D.E. Shaw & Co first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 10 quarters.
  • D.E. Shaw & Co's Acumen Pharmaceuticals position peaked at $1.65M in Q3 2022.
  • 73 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.